TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer.

Cheng-Jiang LiuTing HuPing ShaoWu-Yang ChuYu CaoFeng Zhang

Published in: Gastroenterology research and practice (2021)

TAS-102 monotherapy and combination therapy with bevacizumab can significantly improve the survival of patients and prevent specific adverse events from happening.

Keyphrases

combination therapy
metastatic colorectal cancer
end stage renal disease
newly diagnosed
ejection fraction
prognostic factors
peritoneal dialysis
randomized controlled trial
free survival